Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
22.07 (1y: +15%)
Market Cap 1.25 B P/E(ttm) 20.70
Enterprise Value 1.17 B P/B 4.70
MASI- NAS (USA)
Masimo Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$22.07
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry		 vs
history
Cash to Debt 622.209
MASI's Cash to Debt is ranked higher than
53% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3750.67 vs. MASI: 622.209 )
MASI' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 622.21
Equity to Asset 0.593
MASI's Equity to Asset is ranked higher than
64% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.53 vs. MASI: 0.593 )
MASI' s 10-Year Equity to Asset Range
Min: -3.07   Max: 0.78
Current: 0.59
-3.07
0.78
F-Score: 4
Z-Score: 9.54
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating margin (%) 17.30
MASI's Operating margin (%) is ranked higher than
76% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. MASI: 17.30 )
MASI' s 10-Year Operating margin (%) Range
Min: -13.9   Max: 137.7
Current: 17.3
-13.9
137.7
Net-margin (%) 12.6
MASI's Net-margin (%) is ranked higher than
78% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. MASI: 12.6 )
MASI' s 10-Year Net-margin (%) Range
Min: -14.8   Max: 81.1
Current: 12.6
-14.8
81.1
ROE (%) 22.8
MASI's ROE (%) is ranked higher than
90% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 4.80 vs. MASI: 22.8 )
MASI' s 10-Year ROE (%) Range
Min: 14.6   Max: 319.2
Current: 22.8
14.6
319.2
ROA (%) 16.6
MASI's ROA (%) is ranked higher than
92% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. MASI: 16.6 )
MASI' s 10-Year ROA (%) Range
Min: -17.1   Max: 114.3
Current: 16.6
-17.1
114.3
ROC (Joel Greenblatt) (%) 103.60
MASI's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 14.00 vs. MASI: 103.60 )
MASI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.6   Max: 215.4
Current: 103.6
25.6
215.4
Revenue Growth (%) 9.9
MASI's Revenue Growth (%) is ranked higher than
87% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. MASI: 9.9 )
MASI' s 10-Year Revenue Growth (%) Range
Min: -14.9   Max: 22
Current: 9.9
-14.9
22
EBITDA Growth (%) 2.5
MASI's EBITDA Growth (%) is ranked higher than
81% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. MASI: 2.5 )
MASI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 208.9
Current: 2.5
0
208.9
EPS Growth (%) 5
MASI's EPS Growth (%) is ranked higher than
90% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. MASI: 5 )
MASI' s 10-Year EPS Growth (%) Range
Min: -26.6   Max: 19.2
Current: 5
-26.6
19.2
ยป MASI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

MASI Guru Trades in Q2 2012

Pioneer Investments 257,564 sh (New)
Steven Cohen 62,869 sh (+432.16%)
Joel Greenblatt 94,762 sh (+36.65%)
Ron Baron 1,832,482 sh (+2.07%)
John Burbank Sold Out
Jim Simons 310,200 sh (-35.24%)
» More
Q3 2012

MASI Guru Trades in Q3 2012

Ron Baron 1,793,622 sh (-2.12%)
Jim Simons 289,500 sh (-6.67%)
Pioneer Investments 213,633 sh (-17.06%)
Joel Greenblatt 47,242 sh (-50.15%)
Steven Cohen 1,500 sh (-97.61%)
» More
Q4 2012

MASI Guru Trades in Q4 2012

Paul Tudor Jones 9,700 sh (New)
Pioneer Investments 288,000 sh (+34.81%)
Joel Greenblatt 61,854 sh (+30.93%)
Ron Baron 2,043,622 sh (+13.94%)
Steven Cohen Sold Out
Jim Simons 249,400 sh (-13.85%)
» More
Q1 2013

MASI Guru Trades in Q1 2013

Steven Cohen 20,138 sh (New)
Meridian Funds 264,600 sh (New)
Paul Tudor Jones 20,700 sh (+113.4%)
Jim Simons 528,400 sh (+111.87%)
Joel Greenblatt 101,804 sh (+64.59%)
Pioneer Investments 377,900 sh (+31.22%)
Ron Baron 2,044,041 sh (+0.02%)
» More
» Details

Insider Trades

Latest Guru Trades with MASI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Meridian Funds 2013-03-31 New Buy0.19%$19.51 - $21.33 $ 22.1110%264600
Joel Greenblatt 2013-03-31 Add 64.59%0.04%$19.51 - $21.33 $ 22.1110%101804
Joel Greenblatt 2012-12-31 Add 30.93%0.02%$20.22 - $24.11 $ 22.112%61854
Joel Greenblatt 2012-09-30 Reduce -50.15%0.08%$21 - $24.87 $ 22.11-3%47242
John Burbank 2012-06-30 Sold Out 0.08%$18.35 - $23.98 $ 22.116%0
Joel Greenblatt 2012-06-30 Add 36.65%0.04%$18.35 - $23.98 $ 22.116%94762
John Burbank 2012-03-31 New Buy0.08%$18.46 - $23.49 $ 22.1110%100000
Joel Greenblatt 2012-03-31 Add 110.46%0.07%$18.46 - $23.49 $ 22.1110%69345
Joel Greenblatt 2011-12-31 Add 74.44%0.03%$17.84 - $22.87 $ 22.117%32950
Joel Greenblatt 2011-09-30 New Buy0.07%$20.96 - $30.91 $ 22.11-13%18889
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Masimo Corporation

Weekly CEO Buys Highlight: MDR, MASI, FCH, FGP, FUR
June 10, 2012
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Masimo Corp. CEO Joe Kiani Buys 50,000 Shares
June 4, 2012
Masimo develops innovative monitoring technologies that significantly improve patient care โ€” helping solve "unsolvable" problems. Masimo Corp. has a market cap of $1.08 billion; its shares were traded at around $18.4 with a P/E ratio of 18.1 and P/S ratio of 2.5. Masimo Corp. had an annual average earnings growth of 6.7% over the past 5 years. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 20.70
MASI's P/E(ttm) is ranked higher than
79% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 24.10 vs. MASI: 20.70 )
MASI' s 10-Year P/E(ttm) Range
Min: 16.96   Max: 69.65
Current: 20.7
16.96
69.65
P/B 4.70
MASI's P/B is ranked lower than
73% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. MASI: 4.70 )
MASI' s 10-Year P/B Range
Min: 2.73   Max: 29.02
Current: 4.7
2.73
29.02
P/S 2.50
MASI's P/S is ranked lower than
63% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. MASI: 2.50 )
MASI' s 10-Year P/S Range
Min: 1.77   Max: 9.14
Current: 2.5
1.77
9.14
PFCF 21.10
MASI's PFCF is ranked higher than
66% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 18.60 vs. MASI: 21.10 )
MASI' s 10-Year PFCF Range
Min: 2.33   Max: 71
Current: 21.1
2.33
71
EV-to-EBIT 13.7
MASI's EV-to-EBIT is ranked higher than
65% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 16.25 vs. MASI: 13.7 )
MASI' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 63.9
Current: 13.7
6.3
63.9
PEG 3.9
MASI's PEG is ranked higher than
96% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.23 vs. MASI: 3.9 )
MASI' s 10-Year PEG Range
Min: 1.56   Max: 165.08
Current: 3.9
1.56
165.08
Shiller P/E 22.8
MASI's Shiller P/E is ranked higher than
89% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 23.60 vs. MASI: 22.8 )
MASI' s 10-Year Shiller P/E Range
Min: 13.93   Max: 28.28
Current: 22.8
13.93
28.28

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 16
MASI's Price/Net Current Asset Value is ranked higher than
82% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 8.90 vs. MASI: 16 )
MASI' s 10-Year Price/Net Current Asset Value Range
Min: 15.4   Max: 38.7
Current: 16
15.4
38.7
Price/Tangible Book 5.7
MASI's Price/Tangible Book is ranked higher than
81% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. MASI: 5.7 )
MASI' s 10-Year Price/Tangible Book Range
Min: 4.3   Max: 10.8
Current: 5.7
4.3
10.8
Price/DCF (Projected) 1.7
MASI's Price/DCF (Projected) is ranked higher than
87% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. MASI: 1.7 )
MASI' s 10-Year Price/DCF (Projected) Range
Min: 1.2   Max: 2.3
Current: 1.7
1.2
2.3
Price/Median PS Value 0.6
MASI's Price/Median PS Value is ranked higher than
70% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. MASI: 0.6 )
MASI' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 1.5
Current: 0.6
0.6
1.5
Price/Graham Number 2.3
MASI's Price/Graham Number is ranked higher than
86% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. MASI: 2.3 )
MASI' s 10-Year Price/Graham Number Range
Min: 1.8   Max: 4.6
Current: 2.3
1.8
4.6
Earnings Yield (Greenblatt) 7.30
MASI's Earnings Yield (Greenblatt) is ranked higher than
78% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.95 vs. MASI: 7.30 )
MASI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 15.8
Current: 7.3
1.6
15.8
Forward Rate of Return (Yacktman) 6.84
MASI's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. MASI: 6.84 )
MASI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.1   Max: 24.3
Current: 6.84
0.1
24.3

Business Description

Masimo Corporation was incorporated in California in May 1989 and reincorporated in Delaware in May 1996. On August 13, 2007, the Company completed its initial public offering. Masimo is a global medical technology company that develops, manufactures and markets noninvasive patient monitoring products that improve patient care. The Company develops, manufactures, and markets a family of noninvasive blood constituent patient monitoring solutions that consists of a monitor or circuit board and its proprietary single-patient use and reusable sensors and cables. In addition, it offers remote monitoring and clinician notification solutions, such as the Masimo Patient SafetyNet. It solutions and related products are based upon the proprietary Masimo SET algorithms. The Company invented Masimo Signal Extraction Technology, or Masimo SET, which provides the capabilities of Measure-Through Motion and Low Perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. Pulse oximetry is the noninvasive measurement of the oxygen saturation level of arterial blood, or the blood that delivers oxygen to the body's tissues, and pulse rate. The Company's Masimo SET platform has addressed many of the previous technology limitations and has been referred to by several industry sources as the gold standard in pulse oximetry. The benefits of Masimo SET have been validated in over 100 independent clinical and laboratory studies. This software-based technology is incorporated into a variety of product platforms depending on its customers' specifications. The Company's Masimo SET MS circuit boards perform all signal processing and other pulse oximetry functions incorporating the Masimo SET platform. It next-generation circuit board is the foundation for the Masimo Rainbow SET Pulse CO-Oximetry platform, utilizing technology licensed from Masimo Labs. The MX circuit boards measure arterial blood oxygen saturation levels and pulse rate, and have the circuitry to enable the measurement of total hemoglobin, oxygen content, carboxyhemoglobin, methemoglobin, PVI, and acoustic respiration rate, along with other potential parameters in the future. The Radical-7 incorporates the MX circuit board, which enables Rainbow SET parameters, and offers three-in-one capability to be used as: a standalone device for bedside monitoring; a detachable, battery-operated handheld unit for easy portable monitoring; and a monitor interface via SatShare, proprietary technology allowing its products to work with certain competitor products, to upgrade existing conventional multi-parameter patient monitors to Masimo SET while displaying Rainbow parameters on the Radical-7 itself. The Rad-87, which also contains Masimo Rainbow SET technology, is a compact, lightweight and easy-to-use device designed specifically for use in less acute settings than the Radical-7. The Rad-8 is a bedside pulse oximeter featuring Masimo SET with a low cost design and streamli
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
Traded in other countries:3M4.Germany
ยป More Articles for MASI

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: MDR, MASI, FCH, FGP, FUR Jun 10 2012 
Masimo Corp. CEO Joe Kiani Buys 50,000 Shares Jun 04 2012 
Weekly CEO Buys Highlight: KMI, VGR, SIRO, PNK, MASI Nov 27 2011 
Weekly CEO Buys Highlight: SLM, MASI, ITRI, FLS, PG Nov 06 2011 
Weekly CEO Buys Highlight: MASI, ITRI, FSL, PTP, SLB Oct 29 2011 
Masimo Corp. Reports Operating Results (10-K) Feb 16 2011 
Masimo Corp. Reports Operating Results (10-Q) Nov 03 2010 
Masimo Corp. Reports Operating Results (10-Q) Aug 04 2010 
Masimo Corp. Reports Operating Results (10-Q) May 05 2010 
Masimo Corp. Reports Operating Results (10-K) Feb 17 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial